EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

Mobilization of hematopoietic stem cells with lenograstim in multiple myeloma patients: Prospective multicenter observational study ( KMM122 )

Eun Hee Jung iD, Ja Min Byun iD, Dong-Yeop Shin iD, Young Rok Do iD, Jae-Cheol Jo iD, Sang Min Lee iD, Sung-Soo Yoon iD

Cancer Medicine · 2023

DOI: 10.1002/cam4.5657 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Cancer Medicine, 2023. Verfasst von Eun Hee Jung und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea. Hauptthemen laut MEDLINE: Multiple Myeloma, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Current guidelines recommend using filgrastim or tbo‐filgrastim to mobilize hematopoietic progenitor cells in an autologous setting. However, previous studies have suggested other forms of granulocyte colony‐stimulating factor (G‐CSF) are equally efficacious, possibly with fewer leukaphereses required. Thus, we prospectively studied the efficacy of lenograstim, a glycosylated recombinant form of G‐CSF, in multiple myeloma (MM) patients.

Methods

From November 2011 to January 2020, 98 MM patients undergoing autologous stem cell transplant (ASCT) from five academic centers in Korea were enrolled. Patients were mobilized with subcutaneous lenograstim (Neutrogin®) with fixed doses of 10 μg/kg for 4 days.

Results

Most of the patients ( N = 90, 91.8%) achieved at least the targets of 2 × 10 6 CD34+ cells/kg body weight, and more than half of MM patients ( N = 57, 58.2%) reached a target of 5 × 10 6 CD34+ cells/kg body weight. The mobilization failure rate was 8.2% ( N = 8). The median number of CD34 + cell/kg using G‐CSF only was 5.25 × 10 6 /kg (range 0.49–13.47). Adverse events included transfusion (TF, N = 53, 54.1%), bone pain ( N = 6, 6.1%), fever ( N = 2, 2.0%), and gastrointestinal troubles ( N = 2, 2.0%). There were no grade 3 or 4 adverse events during mobilization. Body surface area (BSA) at mobilization and platelet TF were factors associated with CD34+ collection. Most patients achieved neutrophil ( N = 93, 98.9%) and platelet ( N = 89, 95.7%) engraftment.

Conclusion

Lenograstim can safely and effectively mobilize stem cells in MM autologous settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaHematopoietic Stem Cell TransplantationHumansLenograstimProspective StudiesHematopoietic Stem Cell MobilizationFilgrastimGranulocyte Colony-Stimulating FactorHematopoietic Stem CellsRecombinant ProteinsAntigens, CD34Transplantation, Autologous

Stichwörter der Autor:innen

G-CSFautologous hematopoietic stem cell transplantationlenograstimmobilizationmultiple myeloma

Substanzen

LenograstimFilgrastimGranulocyte Colony-Stimulating FactorRecombinant ProteinsAntigens, CD34

Autor:innen und Institutionen

  • Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
  • Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
  • Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
  • Center for Medical Innovation, Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea.
  • Department of Internal Medicine, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, South Korea.
  • Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea.

ORCID-Profile: Eun Hee Jung, Ja Min Byun, Dong-Yeop Shin, Young Rok Do, Jae-Cheol Jo, Sang Min Lee, Sung-Soo Yoon

Zitieren

APA

Jung, E. H., Byun, J. M., Shin, D. Y., Do, Y. R., Jo, J. C., Lee, S. M., & Yoon, S. S. (2023). Mobilization of hematopoietic stem cells with lenograstim in multiple myeloma patients: Prospective multicenter observational study ( KMM122 ). Cancer Medicine. https://doi.org/10.1002/cam4.5657

Vancouver

Jung EH, Byun JM, Shin DY, Do YR, Jo JC, Lee SM, et al. Mobilization of hematopoietic stem cells with lenograstim in multiple myeloma patients: Prospective multicenter observational study ( KMM122 ). Cancer Medicine. 2023. doi:10.1002/cam4.5657

BibTeX
@article{Jung2023,
  author = {Jung, Eun Hee and Byun, Ja Min and Shin, Dong-Yeop and Do, Young Rok and Jo, Jae-Cheol and Lee, Sang Min and Yoon, Sung-Soo},
  title = {Mobilization of hematopoietic stem cells with lenograstim in multiple myeloma patients: Prospective multicenter observational study ( KMM122 )},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.5657}
}
Kostenlos starten →